Skip to navigation Skip to content

Myelofibrosis (MF) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051126

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised momelotinib and ruxolitinib for patients with MF.

1 April 2025 changes

As of 1 April 2025 MF has moved to the general schedule and this file will expire.

MF and listing dates

MF is a serious bone marrow disorder that disrupts the body's normal production of blood cells.

Listing dates are:

  • ruxolitinib - February 2016
  • momelotinib - April 2025

Enquiries

Transfer enquiries about prescription arrangements to PBS authority approvals.

The Resources page contains:

  • contact details
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)